An international collaboration led by RIKEN researchers has discovered how unusual spherical structures form in the brains of ...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and (Nasdaq: BIIB, Corporate headquarters: Cambridge, ...

Such amyloid beta fibrils are one of the hallmarks of all forms of Alzheimer's disease, although their structures vary ...

"Amyloid-lowering treatments represent an important advance in the treatment of Alzheimer's disease but they are associated ...

At the same time, hypertension “makes it harder for the brain to remove waste products, such as amyloid beta,” a biological ...

IGC-AD1 significantly impacts both amyloid-beta plaques and tau pathology-two critical drivers in Alzheimer's ...

Presented full dataset from first-in-human Phase 1a clinical trial demonstrating PMN310 was generally well-tolerated with monthly dosing and that ...

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announces that EMA's Committee for Medicinal Products for Human Use (CHMP) has issued ...

The Board of Directors and the Chief Executive Officer of Alzinova AB hereby present the interim report for the period January - September, and the third quarter, 2024. The full interim report, which ...

Annovis Bio (NYSE: ANVS) , a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases, such as Alzheimer's disease ... including amyloid beta, tau, ...

The interim phase 2 trial results show a good immune response in participants and the therapy is well tolerated to date.

In a report released today, Jason Zemansky from Bank of America Securities maintained a Buy rating on Acumen Pharmaceuticals (ABOS – ...